ArticleMicrobiology spectrum2026
PRV-delgE/gI/TK immunization preserves blood-brain barrier integrity and limits CNS injury following intracerebral PRV challenge.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pseudorabies virus (PRV) causes rapidly progressive and often fatal encephalitis in both natural and non-natural hosts, making the development of effective preventive strategies critically important. Among current vaccine candidates, the triple-gene-deleted PRV strain (PRV-delgE/gI/TK) has been widely studied; however, its protective effects against brain injury, particularly blood-brain barrier (BBB) damage, remain poorly characterized. To address this gap, we established an intracerebral challenge model in C57BL/6J mice to directly evaluate central nervous system (CNS) outcomes following wild-type PRV infection. Wild-type PRV challenge resulted in severe neurological deficits, uniform mortality, extensive neuronal degeneration, pronounced BBB disruption, downregulation of tight junction proteins, strong induction of MMP-2/9, and a robust inflammatory cytokine surge. In contrast, mice immunized with PRV-delgE/gI/TK exhibited only mild and transient symptoms, rapid functional recovery, markedly reduced viral replication, and complete viral clearance by 14 days. Immunization preserved BBB integrity, maintained ZO-1 and occludin expression, prevented MMP activation, and substantially blunted neuroinflammatory responses. Collectively, these results show that PRV-delgE/gI/TK immunization effectively protects against wild-type PRV-induced CNS injury in C57BL/6J mice, as evidenced by reduced viral burden, preserved BBB integrity, and attenuated neuroinflammatory responses, and provide new insight into the neuroprotective effects of attenuated PRV vaccination.IMPORTANCEPseudorabies virus (PRV) can cause severe and often fatal encephalitis, but the central nervous system (CNS)-protective effects of attenuated PRV vaccines remain insufficiently characterized, particularly with respect to blood-brain barrier (BBB) injury. Using a C57BL/6J intracerebral challenge model, this study shows that immunization with the triple-gene-deleted PRV-delgE/gI/TK strain markedly reduces viral replication, preserves BBB integrity, and attenuates neuroinflammatory responses after wild-type PRV challenge. These findings provide
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.